⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21278859 | 1.00 | — | — | |
| SCHEMBL15958459 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL16039611 | 0.96 | — | — | |
| SCHEMBL2333679 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL26107361 | 0.85 | CCR5 (0.38) | — | |
| Oxalic Acid SCHEMBL23150877 | 0.83 | CHRNB2 (0.33) | — | |
| Oxalic Acid SCHEMBL20486055 | 0.83 | CHRNB2 (0.33) | — | |
| Oxalic Acid SCHEMBL20486057 | 0.83 | CHRNB2 (0.33) | — | |
| SCHEMBL18269339 | 0.81 | — | — | |
| SCHEMBL55905 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724442-A1 | AGONISM-ANTAGONISM IN ENDOSOMAL TLRS BY MODULATING CHEMICAL FEATURES IN 8-OXOPURINE: PROCESS FOR PREPARATION AND APPLICATION THEREOF | Council of Scientific and Industrial Research (IN) | 2026-04-15 | — | — | EP | claimed |
| EP-4705300-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | claimed |
| US-12534441-B2 | Tryptamine analogues | Beckley Psytech Limited (GB) | 2026-01-27 | — | — | US | claimed |
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | claimed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | claimed |
| US-12435068-B2 | Anthelmintic compounds | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-10-07 | — | — | US | claimed |
| US-12391682-B2 | Isoquinoline derivatives and their use for the treatment of parasitic infections | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-08-19 | — | — | US | claimed |
| EP-4547666-A1 | METHODS FOR TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION | 2025-04-24 | — | — | US | claimed |
| EP-4003524-B1 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PARASITIC INFECTIONS | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-04-09 | — | — | EP | claimed |
| WO-2018197401-A1 | NEW BICYCLIC PYRAZOLE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2018-11-01 | — | — | WO | claimed |
| WO-2018087036-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2018-05-17 | — | — | WO | claimed |
| EP-2294072-B1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2017-03-29 | — | — | EP | claimed |
| US-20160158229-A1 | Mixtures of Heteropolycycles | LIGHTNER DEREK ALTON (US) | 2016-06-09 | — | — | US | claimed |
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | claimed |
| EP-2643311-A1 | BICYCLIC GPR119 MODULATORS | Lupin Limited (IN) | 2013-10-02 | — | — | EP | claimed |
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | claimed |
| WO-2013005168-A2 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-01-10 | — | — | WO | claimed |
| WO-2012090177-A2 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2012-07-05 | — | — | WO | claimed |
| WO-2012069917-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2012-05-31 | — | — | WO | claimed |